TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
TNF inhibitors are contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
- TRADE NAME: Simponi (Centocor)
- INDICATIONS: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Disease-modifying antirheumatic drug (DMARD), Monoclonal antibody
- HALF-LIFE: 2 weeks
SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of golimumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
